Compare Levi Strauss & Co. (LEVI) vs Summit Therapeutics Inc (SMMT) Price & Performance

Levi Strauss & Co. (LEVI) trades at $19.05, down 2.36% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for four consecutive quarters, including Q3 2026 EPS of $0.48 versus $0.36 expected. Financial health is robust with a net income margin of 8.83% and ROE of 25.76%. Recent news highlights a new CFO appointment and positive analyst expectations for Q3 results driven by denim demand trends.

The investment outlook is positive based on fundamentals and analyst sentiment, with a consensus price target of $29.00 implying significant upside. Risks include competitive pressures, recent cybersecurity incidents, and macroeconomic sensitivity. Wall Street maintains a strong buy consensus, supporting a favorable risk-reward profile for long-term investors.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.